52 results about "Sustained delivery" patented technology

Linkers for linking a therapeutic agent to other moieties, such as an Fc region of an antibody. A linker having two or more maleimide functional groups, which may be subjected to a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by linking a novel linker to the Fc region of an antibody. Antibody drug conjugates having a longer duration of action than the drug alone.

The disclosure relates to microparticles and nanoparticles comprising a porous polymer matrix comprising an uncapped polymer for sustained delivery of a net positively charged therapeutic agent. More particularly the disclosure relates to particles comprising PLGA or PLA which have a first state with relatively more interconnected pores at a first pH and a second state with relatively less interconnected pores at a second pH. Methods of making the particles and administering the particles are also provided.

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

Disclosed are formulations for providing an active agent. Formulations include a carrier including an active agent and mineral coated microparticles wherein an active agent is adsorbed to the mineral. Other formulations include a carrier including mineral coated microparticles wherein mineral coated microparticles include an active agent. Also disclosed are methods for sustained delivery of an active agent and methods for treating inflammatory diseases using a formulation for providing sustained delivery of an active agent.

A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days.

A linker for linking a therapeutic agent to another moiety, such as the Fc region of an antibody. A linker having two or more maleimide functional groups capable of undergoing a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by conjugating it to a novel linker and the Fc region of an antibody. An antibody-drug conjugate having an increased duration of action over the drug alone.

Disclosed are formulations for providing an active agent. Formulations include a carrier including an active agent and mineral coated microparticles wherein an active agent is adsorbed to the mineral. Other formulations include a carrier including mineral coated microparticles wherein mineral coated microparticles include an active agent. Also disclosed are methods for sustained delivery of an active agent and methods for treating inflammatory diseases using a formulation for providing sustained delivery of an active agent.

This invention relates to a silica hydrogel composite comprising inactive silica particles and solid particles of one or more active pharmaceutical ingredients. This silica hydrogel composite enables controlled and sustained delivery of the active pharmaceutical ingredient.

Provided are adhesive dendritic particles, which particles can be used for sustained delivery of an active agent to a location or locations at which the particles are adhered. Also provided are related methods of use and methods of formulating the disclosed particles.

The present invention provides a hydrogel for comprising a biodegradable polyphosphazene polymer, a radiation-sensitive diselenide cross-linker; and one or more payloads releasably loaded within the hydrogel. The present invention further provides methods for radiosensitizing target tissues such as tumors and providing sustained delivery of therapeutics triggered by irradiation. In another aspect, the present invention provides a method that includes: introducing the hydrogel, as describes herein, adjacent to malignant or marginal tissue; and administering radiation to the hydrogel, thereby disrupting the selenocystamine cross-linkers and releasing the one or more payloads.

The invention provides a magnetic soft robot, a preparation method, a control method, a medicine loading method and application. According to the magnetic soft robot, dynamic non-Newtonian hydrogel serves as a main body material, a reversible dynamic cross-linked network is built in the magnetic soft robot, magnetic particles are compounded, a flexible soft structure with the magnetic response capacity is formed, the magnetic soft robot can be remotely driven under the action of an external magnetic field, and the magnetic soft robot is suitable for controllable movement in a limited space. The magnetic soft robot has good biocompatibility and biological safety, and can be used as a drug loading and delivery carrier for preparing a drug preparation; meanwhile, the compound shows good structural stability in a complex physiological environment, and can keep the form and function completeness under various physiological disturbance conditions, thereby supporting continuous delivery of drugs. Finally, the magnetic soft robot provides possibility for medicine preparation and delivery related applications, and is simple in structure, controllable in cost and suitable for popularization and application.

The invention provides sustained delivery of nucleic acids from hydrophobic / organic media, formulations and biomaterial depots.

The invention relates to a method of treating a disease or disorder in a patient in need thereof that includes providing an active pharmaceutical ingredient (API) to the patient by administering more than one split-dose of the API over a pre-determined period of time. In embodiments of the invention, the API is an mRNA encoding an antigen. The attractiveness of mRNA as a vaccine modality is supported by several advantages. As a non-infectious agent that does not require incorporation into the host's genome to confer activity along with its well-defined chemical composition, mRNA is regarded as a relatively safe vaccine modality.

The present invention relates to a novel injectable protein delivery system and a method for delivering one or more therapeutic agents to the central nervous system (CNS) to promote axonal regeneration. The system is based on the use of a recombinant spider silk protein, referred to as spiroin-SpyTag, which undergoes a rapid transition from a sol state to a gel state when exposed to ultrasonic treatment and incubated at body temperature. This unique characteristic allows the material to be easily injected into a specific target tissue. The methods disclosed herein can deliver a protein therapeutic agent covalently conjugated to spiroin-SpyTag to a subject affected by a CNS disorder or injury. In addition, methods of making such injectable protein delivery systems are fast, convenient, and economical and effective.

Provided herein is injectable and / or sprayable, in situ polymerizable collagen-based compositions for sustained delivery of therapeutics (active agents, such as drugs, proteins, and other therapeutic agents). The compositions comprise (i) a neutral collagen solution, which is injectable or sprayable and capable of converting into a fibrous collagen mass or gel upon contacting with a physiological fluid or solution, or water; and (ii) a biologically or pharmaceutically active agent in the neutral collagen solution. The compositions are in the form of clear, transparent viscous solutions that instantaneously undergo gelation and polymerization when contacted by physiological fluids or solutions or water. The collagen solutions can be manipulated to provide various rates of sustained delivery of therapeutics.

To provide a drug delivery system for treating glaucoma or related conditions.SOLUTION: Provided is a drug delivery system comprising (1) a prostaglandin, a CNTF compound, a TNF-α / TNFR inhibitor, a FAS or FASL inhibitor, or any combination thereof, and (2) a sustained delivery component.SELECTED DRAWING: None

Sustained release biologics can be prepared by emulsifying a Solid-in-Hydrocarbon (S / H) mixture in a fluorocarbon solution to form an emulsion of the S / H in the fluorocarbon solution. Advantageously, the Solid-in-Hydrocarbon (S / H) mixture can be prepared by dispersing spray dried biologic particles in a solution of a sustained release polymer in a hydrocarbon solvent. Further, the spray dried biologic particles can be prepared by atomizing a feed solution including a biologic drug in an aqueous carrier to form an aerosol and exposing the aerosol to a stream of drying gas at a temperature of greater than about 80 °C, e.g., from about 80 °C to about 150 °C, to dry the aerosol to form the spray dried biologic particles. In some aspects, emulsifying the S / H mixture in the fluorocarbon solution can be carried out with a microporous membrane.

This invention provides a sustained delivery hydrogel comprising a crosslinked minoxidil-aldehyde-modified polymer for treatment of hair loss. Also provided herein is a sustained delivery hydrogel comprising a crosslinked minoxidil-aldehyde-modified hyaluronic acid derivative for treatment of hair loss. The invention also relates to methods for inducing anagen phase of hair growth, prolonging the anagen phase, increasing hair follicle size, reversing, preventing or inhibiting miniaturization of the hair follicle, and combinations thereof in a subject having hair loss, comprising administering the sustained delivery hydrogel comprising the crosslinked minoxidil-aldehyde-modified hyaluronic acid derivative to an area of hair loss of the subject, and to methods for inducing anagen phase of hair growth, prolonging the anagen phase, increasing hair follicle size, reversing, preventing or inhibiting miniaturization of the hair follicle, and combinations thereof in a subject having hair loss, comprising administering the sustained delivery hydrogel comprising the crosslinked minoxidil-aldehyde-modified polymer to an area of hair loss of the subject.

The subject invention pertains to a novel injectable protein delivery system and methods for delivering one or more therapeutic agents in the central nervous system (CNS) for promoting axon regeneration. This system is based on the use of a recombinant spider silk protein called spidroin-SpyTag, which undergoes a rapid transition from a sol state to a gel state when exposed to ultrasound treatment and incubated at body temperature. This unique characteristic allows the easy injection of the material into a specific target tissue. The methods herein disclosed allow the delivery of protein therapeutics covalently conjugated to the spidroin-SpyTag to a subject affected by a CNS disorder of injury. Additionally, the method for fabricating this injectable protein delivery system is rapid, convenient, and cost-efficient.

The utility model relates to the technical field of corn seed coating, in particular to corn seed coating equipment which comprises a support and a processing mechanism, and the processing mechanism comprises a feeding box, two supporting plates, an annular frame, a feeding assembly, a stirring assembly, a circulating assembly and a spraying assembly. A spiral cutter cylinder in an existing feeding assembly is driven by a feeding motor to continuously rotate, corn materials in a feeding cylinder can be continuously conveyed, workers only need to pour the materials into a feeding box, the time needed for transportation is saved, and the design solves the problem that the materials need to be manually poured into a material frame for multiple times during material processing, so that the labor intensity of workers is lowered. And the problems that the continuity is low, the continuous input and processing of the materials cannot be realized, and the efficiency is low are solved.

To provide compositions and formulations for small-molecule therapeutic agents, and drug-delivery devices comprising compositions and formulations for controlled, sustained delivery of small-molecule therapeutic agents.SOLUTION: Provided is a composition comprising a molar amount of a therapeutic agent that (i) has a water solubility at room temperature of less than 1.0 g / L and (ii) is an organic base, and an organic polyprotic acid in an amount that (i) is equal to or less than the molar amount of the therapeutic agent and (ii) provides a total number of acid hydrogens that exceeds the stoichiometric equivalent for the molar amount of therapeutic agent.SELECTED DRAWING: None

Nanoparticles and nanoparticle-releasing vaginal rings for intermediate- to long-term delivery of drugs to the female genital and reproductive tract have been developed. The nanoparticles are loaded with drugs and coated with a sheddable poly(ethylene glycol) (PEG) layer that promotes mucus penetration and then converts to an adhesive form after penetration. This platform technology readily distributes drug through the mucosa and throughout the vaginal tissue, enhances local retention of drugs within the vaginal tissue, thereby providing a sustained delivery of drugs beyond the natural shedding and turnover of vaginal mucous and epithelial cells.

Provided here within is a saliva-activated pharmaceutical composition for use in an intra-oral sustained-release sachet. The formulation includes acacia powder in defined acacia-to-levodopa ratios effective to increase levodopa solubility by at least 300% at 25° C., maintain a localized pH of 3-5, and suppress levodopa oxidation during and after intra-oral use. In combination with levodopa, carbidopa, ascorbic acid, and optional palatability or swallowing-stimulation agents, the acacia forms a hydrocolloid matrix that stabilizes drug particles, enhances dispersion, and enables sustained, uniform release for several hours. The composition further supports consistent distribution of flavoring agents and prolonged intra-oral retention with improved sensory persistence. This acacia-dependent hydrocolloid system provides controlled salivary dissolution, biochemical stabilization, and predictable sustained delivery of levodopa / carbidopa, achieving performance not obtained with prior acacia-based formulations or with the parent sachet device.

This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease (caspase) inhibitor, including any combination of these compounds and, optionally, a sustained delivery component. This type of drug delivery system can be used to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction. Medicaments, methods of manufacturing medicaments, kits, and other related products or methods are also described.

Hollow hydroxyapatite microparticles are provided for sustained delivery of an agent that provides osteoprotegerin anti-osteolytic activity for treatment of post-orthodontic relapse and bone disorders. In particular, methods of using such microparticles for post-orthodontic tooth stabilization and bone regeneration and repair are provided.

A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days.

Disclosed herein are compositions and methods for modifying B cells. Particles such as hydrophobic microparticles or nanoparticles are described for use in delivering agents to B cells, generating regulatory B cells and inducing IL-10 production by B cells. Particles, or B cells bound to the same, are also provided for use in methods for treating an inflammatory or autoimmune disease or condition, inducing immune tolerance, and sustained delivery of an agent to a subject.

Diffusion-based, implantable devices for the delivery of an opioid antagonist, such as naltrexone, are described. The devices are cylindrical or discoidal in shape and fitted with a biocompatible membrane. These are filled with a compressed formulation of the opioid antagonist, and optionally, a binder. Upon introduction of an aqueous fluid into the device, the compressed formulation erodes at a constant rate along one axis to release the opioid antagonist from the device at a constant rate. The rate is selected to range from approximately 0.02-2.00 mg / day for the treatment of inflammatory, neuroinflammatory, or metabolic disorders.